The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price ...

Deutsche Bank analyst James Shin has maintained their bullish stance on LLY stock, giving a Buy rating on September 16. James Shin has given ...

Eli Lilly's valuation is a critical concern, but its robust execution has improved its ability to actualize its high-growth ...

Discounts of as much as half on the $1,000-plus-a-month injectables are meant to induce insurers to offer coverage to workers ...

Novo Nordisk (NVO) stock is falling Friday morning after the pharmaceutical giant shared that additional weight loss tied to ...

For people who pay out of pocket, Lilly recently introduced vials of its drug Zepbound that cost as little as 399 dollars a month. To compete, Novo Nordisk ramped up its rebating -- average Wegovy ...

We’re firmly in the “buyer beware” era of obesity drugs. And unfortunately, it seems like we’re going to be stuck here for a ...

Novo Nordisk’s obesity drug Wegovy is now recommended by EU regulatory authorities for obesity-related heart conditions.

The 20-year deal with Constellation Energy would kick-start the site of the nation's worst nuclear accident. Top-end German carmakers have joined expensive French handbags among the products hit by ...

Researchers found that patients with obesity had an average weight loss of 12.9% with semaglutide vs 5.6% with liraglutide ...

Novo Nordisk fell more than 4% on Friday to their lowest level since Aug. 10 after the Danish drugmaker reported results from ...